Syntax Research, Inc. Eli Lilly & CO Transaction History
Syntax Research, Inc.
- $156 Billion
- Q3 2025
A detailed history of Syntax Research, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Syntax Research, Inc. holds 140 shares of LLY stock, worth $126,960. This represents 0.07% of its overall portfolio holdings.
Number of Shares
140
Previous 140
-0.0%
Holding current value
$126,960
Previous $109 Million
2.12%
% of portfolio
0.07%
Previous 0.08%
Shares
3 transactions
Others Institutions Holding LLY
# of Institutions
4,474Shares Held
779MCall Options Held
16.9MPut Options Held
12.6M-
Lilly Endowment Inc Indianapolis, IN95.5MShares$86.6 Billion0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA80.4MShares$72.9 Billion1.05% of portfolio
-
Black Rock Inc. New York, NY65.9MShares$59.7 Billion1.37% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA51.3MShares$46.5 Billion26.07% of portfolio
-
State Street Corp Boston, MA34.5MShares$31.3 Billion1.04% of portfolio
About ELI LILLY & Co
- Ticker LLY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 950,174,976
- Market Cap $862B
- Description
- Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...